Pregabalin Capsule
Product Images NDC 71335-1475

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1475). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351475)

These are Pregabalin capsules with a capacity of 100mg, produced by a company called NILD. They come in a package of 30 capsules and are only available by prescription. The package bears a National Drug Code (NDC) number of 71335-1475-01. It is important to store the capsules at room temperature between 20°C-25°C (68°F-77°F) and away from children.*

FDA Label Image

Label (Lbl7133514752)

This text appears to be a comparison between two medications, the one being sold under the name "Pachaged by Bryant Ranck Prepack" and the other being "Lyrica 100mg (CV) Capsule" produced by Laurus Labs Ltd. There is also information on how to store the medication and a warning to keep it out of reach of children. The provided number "08197301523487" may be a product or batch code.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

The text seems to be a chart that shows the percentage of patients who improved, with numbers ranging from 3% to 88%. There is also a line indicating the percentage improvement in pain from the baseline, but the exact value is not given. The last line seems to contain some gibberish characters and does not convey any useful information.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

This is a table showing the percent improvement in pain from baseline for patients who took Pregabalin 160mg for 3 days. The table shows percentages ranging from 2% to 100%. There is also some unclear text that seems to be unrelated to the table.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

This appears to be a chart or table with medication dosages and reported improvements in pain. Without context or further information, it is not possible to provide a useful description.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

This appears to be a table showing the dosages and improvement in pain for three different treatments: Fregabalin 100 mg three times a day, Pregataiin 80 mg three times a day, and placebo. The table also includes the percentage of patients who improved and the percentage of improvement in pain from baseline.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

Not-Available. The given text mainly consists of random characters, numbers, and symbols, and does not form a meaningful description in any language.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

This text appears to be a chart or graph with numerical values indicating percentages and a timeline of days. The chart displays the estimated percentage of subjects without LTR (which could stand for "long-term response") for both a drug called "Pregabain" and a placebo over a 12-day period. The percentages range from 0% to 20%. There is not enough context to understand the nature of the study or what these percentages represent specifically.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

This appears to be a table showing percentages of subjects improved from baseline to week 12 on two different medications: Pregetalin and Placeso. The percentages range from 210 to 240 for an unspecified measurement, and Pregetalin shows a 260% improvement while Placeso shows 100% improvement.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

The text describes a graph or chart showing the percentage of subjects who improved over the course of 16 weeks after taking either Pregabalin or Placebo. The graph includes various percentage values ranging from 100 to 280, with the x-axis displaying week numbers from 210 to 270. There is no further context or information available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.